Tuesday, August 2, 2016

Natera and UCSF Initiate Collaboration to Study DNA Markers of Kidney Transplant Rejection

PR NEWSWIRE | Natera, Inc.

SAN CARLOS, Calif., Aug. 1, 2016 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, announced a research collaboration with the University of California, San Francisco (UCSF), a leader in renal transplantation medicine in North America, to study the level of donor-derived cell-free DNA (dd-cfDNA) in over several hundred retrospectively banked plasma samples from kidney transplant recipients with and without organ injury.

There is a significant unmet need for a more accurate non-invasive diagnostic test for renal transplant care. Currently, physicians rely on a combination of creatinine measures and invasive needle biopsies, which often result in inconclusive results or a diagnosis of acute rejection after the damage to the kidney is irreversible.

Multiple studies have shown dd-cfDNA has a potential to be a universal marker for acute rejection for solid organs. Under this research collaboration, Natera will analyze the dd-cfDNA level of plasma samples collected at UCSF from kidney transplant patients using Natera's proprietary massively-multiplexed PCR (mmPCR) platform and proprietary statistical algorithms. Through this research collaboration, Natera and UCSF will investigate whether the routine measurement of dd-cfDNA can help predict organ injury and ultimately improve clinical outcomes. Continue reading
_______________________________________________________________________
You have the power to SAVE Lives
Please register as an organ, eye and tissue donor today.
In California:
Donate LIFE California | Done VIDA California
Nationwide:
Organ Donor | Donate Life America

...to ensure donation happens, please share your donation decision with your family. At stake is the legacy you plan to leave.

No comments: